SLC5A2 and type 2 diabetes mellitus: The 2023 ESC Guidelines suggest, with a class I recommendation, that individuals with T2DM identified as being at a very high risk should initiate treatment with glucose-lowering medication with proven CV benefits, such as SGLT-2 inhibitors and/or GLP-1 receptor agonists, independent of HbA1c levels [11].